A5073000306- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer survivorship and care
- Breast Lesions and Carcinomas
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Cutaneous Melanoma Detection and Management
- Cancer-related cognitive impairment studies
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Childhood Cancer Survivors' Quality of Life
- Statistical Methods in Clinical Trials
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Family Support in Illness
- Breast Implant and Reconstruction
- Inflammatory mediators and NSAID effects
- Immune Cell Function and Interaction
Breast Cancer Trials
2013-2025
The University of Sydney
2015-2025
International Breast Cancer Study Group
2012-2022
National Health and Medical Research Council
2002-2021
Peter MacCallum Cancer Centre
2007-2019
Garvan Institute of Medical Research
2012-2019
St Vincent's Hospital Sydney
2019
Cancer Council Australia
2000-2018
Dana-Farber Cancer Institute
2006-2018
Frontier Science & Technology Research Foundation
2001-2018
The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on recognition intrinsic biological subtypes within breast cancer spectrum. For practical purposes, these may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow subtype classification. Thus, 'Luminal A' disease generally requires only...
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Tamoxifen, taken for five years, is the standard adjuvant treatment postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse.We conducted double-blind, randomized trial to test whether, after two three years of tamoxifen therapy, switching exemestane was more effective than continuing therapy remainder treatment. The primary end point disease-free survival.Of 4742 enrolled, 2362 were randomly assigned switch...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and in the neoadjuvant setting than tamoxifen. We compared with tamoxifen as adjuvant steroid-hormone-receptor-positive postmenopausal women.The Breast International Group (BIG) 1-98 study randomized, phase 3, double-blind trial that five years of various endocrine therapy regimens women hormone-receptor-positive cancer: letrozole, followed by tamoxifen, letrozole. This analysis compares two groups...
The 11(th) St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level estrogen receptor (ER) expression is considered sufficient justify use endocrine therapy almost all patients. Overexpression or amplification HER2 standard criteria indication for anti-HER2 but very lowest risk invasive tumours. corollary...
Previous analyses of the Breast International Group (BIG) 1-98 four-arm study compared initial therapy with letrozole or tamoxifen including patients randomly assigned to sequential treatment whose information was censored at time change. Because this presentation may unduly reflect early events, present analysis is limited continuous arms and includes protocol-defined updated results.Four thousand nine hundred twenty-two 8,028 postmenopausal women receptor-positive breast cancer...
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Suppression of ovarian estrogen production reduces the recurrence hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.We randomly assigned 3066 stratified according prior receipt or nonreceipt chemotherapy, receive 5 years tamoxifen, plus suppression, exemestane suppression. The primary analysis tested hypothesis that suppression would improve disease-free survival, as compared with alone. In analysis, 46.7% patients had...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
Since chemotherapy for metastatic breast cancer is not curative, consideration of the quality life important in selecting a treatment regimen. We conducted randomized trial comparing continuous chemotherapy, administered until disease progression was evident, with intermittent therapy, whereby stopped after three cycles and then repeated more only when there evidence progression. Each approach tested doxorubicin combined cyclophosphamide or methotrexate, fluorouracil, prednisone....
Predicting the pattern of recurrence can aid in development targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event a median follow-up 24 years from diagnosis operable breast cancer.International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 1985. Annualized hazards were estimated cancer-free interval (primary end point), disease-free survival, overall survival.For entire group,...
The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women receptor-positive early breast cancer. It is unknown whether sequential treatment tamoxifen and letrozole superior to therapy alone.In this randomized, phase 3, double-blind trial of the hormone-receptor-positive cancer in women, we randomly assigned receive 5 years monotherapy, or 2 one agent followed by 3 other. We treatments monotherapy 6182 also report a...
To determine how patients with infiltrating lobular carcinoma (ILC) differ from the more common ductal (IDC) regard to patient and tumor factors, local treatment, patterns of recurrence.Twelve thousand two hundred six breast cancer entered onto 15 International Breast Cancer Study Group trials between 1978 2002 were categorized as having ILC, IDC, or other/mixed types.Seven sixty-seven tumors (6.2%) classified 8,607 (70.5%) 2,832 (23.2%) other. The analysis is limited 9,374 either pure IDC...
To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women early breast cancer.Breast International Group (BIG) 1-98 randomly assigned 8,010 patients to four arms comparing sequences each agent. The Central Pathology Office received material for 6,549 (82%), which 79% were assessable (6,291 patients). Prognostic predictive value both local central hormone...